Pdac - pancreatic ductal adenocarcinoma

Researchers are testing whether adding two oral drugs, avutometinib and defactinib, to standard chemotherapy (mFOLFIRINOX) is safe and can slow or shrink pancreatic ductal adenocarcinoma. The trial has two parts: one for people whose cancer has spread, and one for people whose ca…

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This Phase III trial tests whether adding targeted radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 198 participants who have not had prior treatment will be randomly assigned to receive …

This registry study follows 400 people at increased risk for pancreatic ductal adenocarcinoma who receive PancreaSure, a blood test designed to detect early-stage disease. Researchers track whether the test results lead doctors to change surveillance plans, such as scheduling mor…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This study is a registry that collects medical information and biological samples from up to 100,000 people with gastrointestinal cancers, such as pancreatic or colorectal cancer. No new treatments or drugs are given. The goal is to gather real-world data to help researchers answ…